Evidence map›Paper›PMID 34208308›Full record

ArticleCells2021

Anti-CD20 Therapy Alters the Protein Signature in Experimental Murine AIH, but Not Exclusively towards Regeneration.

Laura Elisa Buitrago-Molina, Janine Dywicki, Fatih Noyan, Lena Schepergerdes, Julia Pietrek, Maren Lieber, Jerome Schlue, Michael P Manns, Heiner Wedemeyer, Elmar Jaeckel and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Experimental Models of Autoimmune Hepatitis: Disease Fidelity and Translational Relevance.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Laura Elisa Buitrago-MolinaDepartment of Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, 30625 Hannover, Germany.ORCID 0000-0002-0051-2044
Janine DywickiDepartment of Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, 30625 Hannover, Germany.
Fatih NoyanDepartment of Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, 30625 Hannover, Germany.
Lena SchepergerdesDepartment of Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, 30625 Hannover, Germany.
Julia PietrekDepartment of Gastroenterology and Hepatology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.
Maren LieberDepartment of Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, 30625 Hannover, Germany.
Jerome SchlueInstitute of Pathology, Hannover Medical School, 30625 Hannover, Germany.
Michael P MannsDepartment of Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, 30625 Hannover, Germany.
Heiner WedemeyerDepartment of Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, 30625 Hannover, Germany.
Elmar JaeckelDepartment of Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, 30625 Hannover, Germany.
Matthias Hardtke-WolenskiDepartment of Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, 30625 Hannover, Germany.ORCID 0000-0002-2827-7787
Medizinische Hochschule Hannover · DEUniversity of Duisburg-Essen · DE

Funding

Deutsche Forschungsgemeinschaft BU2722/2-1Deutsche Forschungsgemeinschaft BU2722/2-3Deutsche Forschungsgemeinschaft HA 6880/2-1Deutsche Forschungsgemeinschaft HA 6880/2-3Deutsche Forschungsgemeinschaft KFO250; Project 7
6 · The paper itself

Abstract

backgroundAutoimmune hepatitis (AIH) is a chronic autoimmune inflammatory disease that usually requires lifelong immunosuppression. Frequent recurrences after the discontinuation of therapy indicate that intrahepatic immune regulation is not restored by current treatments. Studies of other autoimmune diseases suggest that temporary depletion of B cells can improve disease progression in the long term.

methodsWe tested a single administration of anti-CD20 antibodies to reduce B cells and the amount of IgG to induce intrahepatic immune tolerance. We used our experimental murine AIH (emAIH) model and treated the mice with anti-CD20 during the late stage of the disease.

resultsAfter treatment, the mice showed the expected reductions in B cells and serum IgGs, but no improvements in pathology. However, all treated animals showed a highly altered serum protein expression pattern, which was a balance between inflammation and regeneration.

conclusionsIn conclusion, anti-CD20 therapy did not produce clinically measurable results because it triggered inflammation, as well as regeneration, at the proteomic level. This finding suggests that anti-CD20 is ineffective as a sole treatment for AIH or emAIH.

Indexed as

RegenerationAnimalsAntibodies, MonoclonalAntigens, CD20AutoantibodiesB-LymphocytesHepatitis, AutoimmuneHep G2 CellsHumansImmunosuppression TherapyInflammationMiceMice, Inbred NODProteomeAntibodies, MonoclonalAntigens, CD20AutoantibodiesProteomeanti-CD20 therapyautoimmune hepatitishepatic inflammationimmune toleranceregeneration

Identifiers

PMID34208308
PMCPMC8231180
OpenAlexW3170053477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.